Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans
該当なし
完了
NCT03077360
| 対象疾患 | Diabetes Mellitus, Type 2, Pre-diabetes, Obesity |
|---|
| 相 | 該当なし |
|---|
| スポンサー | University of Colorado, Denver |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 62 名 |
|---|
| 介入(薬剤) | Lifestyle |
|---|
| 開始日 | 2017年2月1日 |
|---|
| 完了日 | 2020年11月19日 |
|---|
| 結果公開日 | 2022年6月21日 |
|---|
概要
The rationale for the proposed research is that elucidating changes in localized diacylglycerol (DAG) and sphingolipid species that predict insulin sensitivity will reveal specific localized lipids to target in therapeutics for type 2 diabetes. To attain the overall objective, the investigators propose three specific aims: 1. Identify the influence of sarcolemmal DAG and sphingolipids on cell signaling and insulin sensitivity before and after insulin sensitizing lifestyle interventions. Strong preliminary data shape the hypothesis that sarcolemmal 1,2-disaturated DAG and C18:0 ceramide species will decrease after insulin sensitizing lifestyle interventions, leading to less Protein kinase C (PKC) and Protein phosphatase 2A (PP2A) activation, and enhanced insulin signaling. Skeletal muscle DAG and sphingolipid isomers, species, localization, and de novo synthesis will be measured before and after diet-induced weight loss or exercise training interventions in obese men and women. Insulin sensitivity will be measured using insulin clamps, and muscle lipids using Liquid Chromatography Mass Spectrometry (LC/MS). 2. Determine the impact of mitochondrial/ER (endoplasmic reticulum) DAG and
Percent Change in Insulin Sensitivity Compared to Baseline Measurement.
Baseline and 12 weeks · Percent change
| Weight Loss Only | 31.8 ± 8.8 Percent change |
|---|
| Exercise Only | 17.4 ± 8.7 Percent change |
|---|
| Delayed Intervention Control | -4.8 ± 9.3 Percent change |
|---|
Percent Change in Localized Muscle Lipids Compared to Baseline
Baseline and 12 weeks · percentage change
| Weight Loss Only | -25 ± 6 percentage change |
|---|
| Exercise Only | -30 ± 7 percentage change |
|---|
| Delayed Intervention Control | 5 ± 6 percentage change |
|---|
| Weight Loss Only | -20 ± 5 percentage change |
|---|
| Exercise Only | -25 ± 5 percentage change |
|---|
| Delayed Intervention Control | 10 ± 3 percentage change |
|---|
Percent Change in Body Weight Compared to Baseline Measurement
Baseline, 3 Months · Percent Change
| Weight Loss Only | -10.5 ± 0.9 Percent Change |
|---|
| Exercise Only | -0.5 ± 0.5 Percent Change |
|---|
| Delayed Intervention Control | 0.5 ± 0.4 Percent Change |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。